Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In patients at high risk of relapse, adjuvant therapy with Keytruda prolonged disease-free survival.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
75% of people treated with a combination of immunotherapy, targeted therapy and chemotherapy saw their tumors shrink.
However, a majority of these chronic immune-related side effects were mild.
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
Keytruda can treat women whose endometrial cancer cells have certain characteristics.
First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.
Keytruda plus chemotherapy should be a new standard of care as first-line therapy in patients with esophageal cancer, say researchers.
The checkpoint inhibitor is approved for adults and children with relapsed lymphoma.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.